Amino acids and peptides. XXI. Laminin-related peptide analogs including poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. 1994

K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Japan.

Laminin-related peptides, Tyr-Ile-Gly-Ser-Arg analogs, were prepared and their inhibitory effects on experimental metastasis were examined. Of the amino acids in the Tyr-Ile-Gly-Ser-Arg sequence, L-Arg was very important and Ile was not essential for the inhibitory effect. To obtain a potent inhibitor of metastasis, hybrids of Tyr-Ile-Gly-Ser-Arg-Gly and 2 types of poly(ethylene glycol) were prepared. The inhibitory effects of the hybrids were more potent than that of Tyr-Ile-Gly-Ser-Arg-Gly.

UI MeSH Term Description Entries
D007797 Laminin Large, noncollagenous glycoprotein with antigenic properties. It is localized in the basement membrane lamina lucida and functions to bind epithelial cells to the basement membrane. Evidence suggests that the protein plays a role in tumor invasion. Merosin,Glycoprotein GP-2,Laminin M,Laminin M Chain,Chain, Laminin M,Glycoprotein GP 2,M Chain, Laminin
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000596 Amino Acids Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. Amino Acid,Acid, Amino,Acids, Amino
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
December 1995, Biological & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
December 1995, Chemical & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
February 1998, Chemical & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
December 1991, Chemical & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
April 2001, Chemical & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
June 1996, Biological & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
July 1998, Biochemical and biophysical research communications,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
November 1997, Chemical & pharmaceutical bulletin,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
December 1997, Biochemical and biophysical research communications,
K Kawasaki, and T Murakami, and M Namikawa, and T Mizuta, and Y Iwai, and Y Yamashiro, and T Hama, and S Yamamoto, and T Mayumi
September 1994, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!